Coronary Microvascular Dysfunction Clinical Trial
An Open-Label Exploratory Clinical Study to Evaluate the Safety and Potential Bioactivity of CLBS14 in Patients With Coronary Microvascular Dysfunction (CMD) and Without Obstructive Coronary Artery Disease
This clinical trial will explore the safety and effect of GCSF-mobilized autologous ex vivo selected CD34 cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single intracoronary infusion of CLBS14.
|Source||Caladrius Biosciences, Inc.|
|Start date||April 19, 2018|
|Completion date||April 2020|